139669-95-7

Usage

Chemical Properties

Brown powder

InChI:InChI=1/C4HBr2NOS/c5-3-2(1-8)9-4(6)7-3/h1H

Upstream product

• 4175-77-3 2,4-dibromo-1,3-thiazole 
• 68-12-2 N,N-dimethyl-formamide 
• 2295-31-0 thiazoline-2,4-dione 
• 21295-51-2 phosphoryl(III) bromide 

Downstream Products

• 170232-68-5 (2,4-dibromo-1,3-thiazol-5-yl)methanol 
• 139669-96-8 2,4-dibromo-1,3-thiazole-5-carboxylic acid 
• 1003-32-3 thiazole-5-carboxaldehyde 

Relevant academic research and scientific papers

A novel and efficient synthesis of 5-(hydroxymethyl)thiazole: An important synthon for preparing biologically active compounds

A novel and efficient synthesis of 5-(hydroxymethyl)thiazole, an important synthon for the preparation of biologically active compounds, is described. The research also provides additional insight into the properties of halothiazoles.

AMINO HETEROCYCLIC COMPOUNDS AND USES THEREOF

The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory, and autoimmune diseases and cancers.

2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS

Compounds of formula I (formula I), wherein A is an optionally substituted five-membered unsaturated heterocyclic ring containing 1, 2 or 3 N, O or S ring heteroatom(s) exhibit alpha2C antagonistic activity and are thus useful for the treatment of diseases or conditions of the peripheric or central nervous system.

CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA]

The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide or sulfonamide containing cyclic compounds of Formula (1), (1'), (100), (100'), (200) and (200') and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.

Thiazolyl-benzimidazoles

The invention is directed to compounds of formula (1) [image] and pharmaceutically acceptable salts thereof, methods for the preparation thereof, and methods of use thereof.

6-O-substituted erythromycin derivatives having improved gastrointestinal tolerance

Compounds having formula (I) are useful for treating bacterial infections while avoiding the concomitant liability of gastrointestinal intolerance. Compositions containing the compounds and methods of treatment using the compounds are also disclosed.

Synthesis of the PPARβ/δ-selective agonist GW501516 and C4-thiazole-substituted analogs

Sequential, position-selective, Pd-catalyzed cross-coupling reactions of 2,4-dibromo-5-hydroxymethylthiazole provided the scaffold for the synthesis of GW501516, the most potent PPARβ/δ agonist yet described, and equally selective analogs at the thiazole-

Pyrrolopyrimidines as therapeutic agents

Chemical compounds having structural formula I and physiologically acceptable salts and metabolites thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases, whose activity is inhibited by these chemical compounds, are involved in immunologic, hyperproliferative, or angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyper proliferative disorders, rheumatiod arthritis, disorders of the immune system, trasplant refections and imflammatory disorders.

Azoles. Part 8. Metallation and Bromine -> Lithium Exchange Reactions of Polyhalogenothiazoles

2,4-Dichloro- and 2,4-dibromo-thiazole were deprotonated at position-5 with LiN(iPr)2 in THF at -78 deg C and the resulting lithium compound was quenched with various reagents, to yield various trisubstituted thiazoles. 2,5-Dibromo-4-chlorothiazole reacted with n-butyllithium in THF at -78 deg C at position-5 and the resulting lithium derivative gave 2-bromo-4-chloro-5-substituted thiazoles when quenched with the appropriate reagent.Both the 2- and 5-bromine-atoms were reactive in diethyl ether. 2,5-Dibromothiazole failed to deprotonate at position-4 under various reaction conditions, whereas treatment of 2,4,5-tribromothiazole with 1 mole equivalent of n-butyllithium in THF at -90 deg C, followed by addition of dimethyl disulfide after 30 min, gave a high yield of the 2,5-bis(methylthio)-compound.The tribromo-compound was also treated with 1 mole equivalent of n-butyllithium or methyllithium under various reaction conditions and the products formed after hydrolysis were analysed by 1H NMR spectroscopy.The 5-bromine-atom is the most reactive and greater selectivity is obtained with methyllithium.